Developing The Formulation: 18 Lacap, Dixie Mae N
Developing The Formulation: 18 Lacap, Dixie Mae N
Developing The Formulation: 18 Lacap, Dixie Mae N
FORMULATION
18 LACAP, DIXIE MAE N.
What is
the GOAL?
To prepare a capsule with:
> Accurate dosage
> Good bioavailability
> Ease of filling &
production stability
> Elegance
DRY FORMULATIONS
- active and inactive components must be blended
thoroughly to ensure a uniform powder mix for the fill.
LOW-DOSE DRUGS
Care in blending
Lack of homogeneity in blending may result in
significant therapeutic consequences.
PRE-FORMULATION STUDIES
To determine:
if all the formulations bulk powders may be
effectively blended together.
require reduction of particle size
any other processing to achieve homogeneity
DILUENT/FILLER
added to the
formulation to
produce the proper
capsule fill
volume
provides bulk and
cohesion to the
powder
beneficial in
transferring
powder blends into
capsule shells
DISINTEGRANTS
> Assist the breakup and distribution of the
capsule
s waterproofing
characteristics
can
t be penetrated by the
gastrointestinal fluids
delays drug dissolution & absorption
useful for modied release capsule
SODIUM LAURYL
SULFATE
surface active
agent
facilitates
wetting by the GI
fluids
is added to aid
drug dissolution
and absorption
delay
DISINTEGRATION
AGENTS
facilitates breakup and
distribution of the
capsule
s content
aids GI fluids to
displace the air around
the powder for the
penetration to occur
and drug dispersion and
dissolution to start
microcrystalline cellulose
Why do we INSERT CAPSULES/
TABLETS inside capsules?
to separate chemically
incompatible agents
to add pre-measured
amounts of potent drug
subs.
rather than weighing a potent
drug
COATED PELLETS
(industrial scale)
designed for
modified release
drug delivery
commonly placed in
capsule shells
DICLOMAX
diclofenac
SLOW RELEASE
GELATIN CAPSULES
unsustainable for
aqueous liquids
water softens
gelatin, causing
leakage
GELATIN CAPSULES
FIXED OR VOLATILE OIL
do not interfere with gelatin shell
stability
LOCKING GELATIN CAPSULES/ Capsule
sealed with a THIN COAT OF GELATIN
WET MASS/PASTE
fixed/volatile oil with INERT POWDER
placed in caps. in usual manner
ex POLYETHER
EUTECTIC MIXTURES
mixtures of agents that have a propensity
to liquefy when admixed
mixed with a DILUENT/ADSORBENT to
separate interacting agent & to absorb
any liquefied material that may form
LARGE SCALE CAPSULE
PRODUCTION
liquids are placed in SOFT GELATIN
CAPSULES that are sealed during filling &
manufacturing
IND. VS COMMUN.
slight loss in fill material during
preparation & capsule filling will not
materially affect an industrial sized
batch
slight loss of powder could result in an
inadequate quantity to fill the last
capsule
CP can calculate in excess of 1 or two capsules more than what is
required to ll the capsule EXCEPT when dealing with capsules
containing controlled subs!
amount of drug used & called for must STRICTLY COINCIDE
SELECTING THE
CAPSULE SIZE
18 LACAP, DIXIE MAE N.
DURING PRODUCT
DEVELOPMENT
FORMULATION
REQUIREMENTS
dose of the active ingredient
density and compaction
characteristics
Diluents are added when dose of the
drug is inadequate to fill the volume
of the capsule body
GUIDE IN SELECTING
CAPSULE SIZE
density & compaction characteristics
of a capsule